RAB28 and cone-rod dystrophy: As small GTPases are good drug targets, it should be feasible to develop a RAB28 inhibitor, however, given the association of RAB28 with cone rod dystrophy, future work is required to determine if chronic treatment with such an inhibitor is a feasible therapeutic option.